regardless of encouraging clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant resistance from PBMs. These insurers are typically creating barriers to coverage, including significant price restrictions and approval processes that limit consumer access. Analysts